US EditionPublished • loading... • Updated
Semaglutide helps heart regardless of how much weight lost, study reveals
Semaglutide cuts major cardiovascular events by 20% in overweight adults with heart disease, with benefits largely unrelated to weight loss, researchers found.
- On October 22 researchers reported semaglutide reduced major adverse cardiovascular events regardless of weight loss in the SELECT trial of over 17,000 adults aged 45 and over, published in The Lancet journal.
- Building on earlier 20% findings, researchers re‑examined the SELECT trial to test if cardiovascular benefits were due to weight loss or other mechanisms, using prespecified data presented last year.
- The team found waist circumference reduction mediated an estimated 33 per cent of the benefit on heart events, with each 5‑centimetre drop linked to about a 9 per cent lower risk.
- Clinicians said researchers suggest Wegovy use should not be limited to severely obese patients; last year the UK medicines regulator approved it and the NHS in England will roll out jabs to 240,000 people.
- Future trials should explore the roles of blood vessel lining, blood pressure, blood sugar, inflammation, and responses by ethnicity and sex, as two thirds of the benefit remain unexplained.
Insights by Ground AI
11 Articles
11 Articles
NewScientistReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsWegovy has heart health benefits even if weight loss is minimal
Studies have suggested that Wegovy directly boosts heart health, beyond just the benefits of losing weight, and now that has been demonstrated in a robust trial in people
·Baltimore, United States
Read Full Article
Coverage Details
Total News Sources11
Leaning Left4Leaning Right1Center3Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 38%
12%
Factuality
To view factuality data please Upgrade to Premium
